Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.

Authors:
  • JSJ. A. Sloan
    J. A. Sloan
  • MMM. R. Mahoney
    M. R. Mahoney
  • DSD. J. Sargent
    D. J. Sargent
  • JHJ. M. Hubbard
    J. M. Hubbard
  • HLH. Liu
    H. Liu
  • EBE. M. Basch
    E. M. Basch
  • ASA. F. Shields
    A. F. Shields
  • ECE. Chan
    E. Chan
  • RGR. M. Goldberg
    R. M. Goldberg
  • SGS. Gill
    S. Gill
  • MKM. S. Kahlenberg
    M. S. Kahlenberg
  • SAS. R. Alberts
    S. R. Alberts
Publisher website
Google Scholar
Abstract
6122 Background: Despite the potential therapeutic advantage, only approximately 5% of eligible adult cancer patients enter oncology clinical trials. Knowledge of whether patients thought the clinical trial experience was beneficial may provide insights for barriers to accrual and inform future trial design. A recent phase III study in stage III colon cancer, N0147, included the 5-item “Was It Worth It” (WIWI) patient questionnaire to assess patient satisfaction. We report the results here. Methods: Patients received 12 bi-weekly cycles of FOLFOX alone or with cetuximab. WIWI was completed at treatment discontinuation. Comparisons between groups for each WIWI item was carried out via Fisher’s exact tests. Results: WIWI data was provided by 1081 patients (see table). The majority said trial participation was worth it (95%), would do it again (90%), would recommend it to other people (95%), and that their QOL was improved by going on trial (65%). Over one-third of patients (37%) said their satisfaction was ...